Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05730205 · ClinicalTrials.gov registry record · Phase 4
Effects of the Contraceptive Implant in Women With Sickle Cell Disease
A Phase 4 study of Sickle Cell Disease, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT05730205 is a Phase 4 study of Sickle Cell Disease that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 22 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05730205, a Phase 4 study of Sickle Cell Disease, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to measure the acceptability and impact of the progestin implant on frequency of vaso-occlusive crises, quality of life, and hematologic parameters in women with SCD.
Conditions Studied
Interventions
- DRUG Nexplanon 68 MG Drug Implant
Study Locations (1)
Pennsylvania
- Penn Medicine University City - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2023-06-08 |
| Est. Completion | 2026-06-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05730205
The ClinicalTrials.gov registry entry for NCT05730205 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (92% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Nexplanon 68 MG Drug Implant is the first listed.
NCT05730205 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05730205 about?
NCT05730205 is a clinical study titled "Effects of the Contraceptive Implant in Women With Sickle Cell Disease". The objective of this study is to measure the acceptability and impact of the progestin implant on frequency of vaso-occlusive crises, quality of life, and hematologic parameters in women with SCD.
What is the current status of trial NCT05730205?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2023-06-08. Estimated completion is 2026-06-15.
What conditions does trial NCT05730205 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT05730205?
The interventions under investigation include: Nexplanon 68 MG Drug Implant (DRUG).
Who is sponsoring clinical trial NCT05730205?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05730205 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease
RECRUITING · Phase 4
-
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
RECRUITING · Phase 4
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.